Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14336558 | 0.81 | METAP2 (0.44) | HSD17B10HTTMETAP2METAP1ALDH1A1 | |
| SCHEMBL2202798 | 0.81 | METAP2 (0.44) | HSD17B10HTTMETAP2METAP1NR3C1 | |
| SCHEMBL23452695 | 0.76 | METAP2 (0.40) | HSD17B10HTTMETAP2METAP1NR3C1 | |
| SCHEMBL10694869 | 0.75 | METAP2 (0.39) | HSD17B10HTTMETAP2METAP1NR3C1 | |
| SCHEMBL3801779 | 0.75 | METAP2 (0.47) | HSD17B10HTTMETAP2METAP1NPY5R | |
| SCHEMBL5436671 | 0.74 | METAP2 (0.41) | HSD17B10HTTMETAP2METAP1NPY5R | |
| SCHEMBL10552256 | 0.74 | METAP2 (0.38) | HSD17B10HTTMETAP2METAP1NR3C1 | |
| SCHEMBL23452690 | 0.74 | METAP2 (0.38) | HSD17B10HTTMETAP2METAP1NR3C1 | |
| SCHEMBL10600444 | 0.74 | METAP2 (0.48) | HSD17B10HTTMETAP2METAP1ALDH1A1 | |
| SCHEMBL11219412 | 0.73 | HTT (1.00) | HSD17B10HTTNPSR1HCAR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1529049-A2 | DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2005-05-11 | — | — | EP | claimed |
| WO-2004014913-A2 | DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-02-19 | — | — | WO | claimed |
| EP-1383767-A1 | TRIFLUOROMETHYLPURINES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2004-01-28 | — | — | EP | claimed |
| WO-2002098878-A1 | TRIFLUOROMETHYLPURINES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2002-12-12 | — | — | WO | claimed |
| EP-2377865-B1 | CYCLOBUTYL PURINE DERIVATIVE, ANGIOGENESIS PROMOTING AGENT, LUMENIZATION PROMOTING AGENT, NEUROCYTE GROWTH PROMOTING AGENT, AND DRUG | UNIV KAGAWA NAT UNIV CORP (JP) | 2014-12-17 | — | — | EP | disclosed |
| EP-1638559-B1 | USE OF PYRAZOLOPYRIDINES FOR THE TREATMENT OF COGNITIVE DEFICITS | EXONHIT THERAPEUTICS SA (FR) | 2010-01-06 | — | — | EP | disclosed |
| US-7371737-B2 | 2-substituted-6-trifluoromethyl purine derivatives with adenosine-A3 antagonistic activity | SOLVAY PHARMACEUTICALS, B.V. (NL) | 2008-05-13 | — | — | US | disclosed |
| EP-1797092-A1 | 2-SUBSTITUTED-6-TRIFLUOROMETHYL PURINE DERIVATIVES WITH ADENOSINE-A3 ANTAGONISTIC ACTIVITY | Solvay Pharmaceuticals B.V. (NL) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006027365-A1 | 2-SUBSTITUTED-6-TRIFLUOROMETHYL PURINE DERIVATIVES WITH ADENOSINE-A3 ANTAGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-03-16 | — | — | WO | disclosed |
| US-20060052331-A1 | 2-Substituted-6-trifluoromethyl purine derivatives with adenosine-A3 antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-03-09 | — | — | US | disclosed |
| EP-1529049-A2 | DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004014913-A2 | DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
| US-6511984-B2 | For therapy of feeding disorders, cardiovascular diseases and other physiological disorders related to an excess of neuropeptide Y | PFIZER INC. | 2003-01-28 | — | — | US | disclosed |
| US-20020058671-A1 | Neuropeptide Y antagonists | ELLIOTT RICHARD L (US) | 2002-05-16 | — | — | US | disclosed |
| EP-0538332-B1 | POLYCYCLIC GUANINE DERIVATIVES | SCHERING CORP (US) | 1997-07-23 | — | — | EP | disclosed |
| US-5393755-A | Hypotensive agents, enzyme inhibitors | SCHERING CORPORATION (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0538332-A1 | POLYCYCLIC GUANINE DERIVATIVES. | SCHERING CORP (US) | 1993-04-28 | — | — | EP | disclosed |
| WO-1991019717-A1 | POLYCYCLIC GUANINE DERIVATIVES | SCHERING CORPORATION (US) | 1991-12-26 | — | — | WO | disclosed |
| EP-0395977-A1 | Process for the preparation of 4-hydroxy-6-polyfluoroalkylpyrimidines | LONZA AG (CH) | 1990-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058671-A1 | Neuropeptide Y antagonists | NPY1R, NPY2R, GIPR | HSD17B10 1548/4885HTT 1150/4885METAP2 1664/4885 |
| US-20060052331-A1 | 2-Substituted-6-trifluoromethyl purine derivatives with adenosine-A3 antagonistic activity | ADORA3, ADORA2A, ADORA2B | HSD17B10 4423/4885HTT 4511/4885METAP2 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.